wherein:

R_1 and R_2 are independently selected from hydrogen and alkyl;

R_3 is alkyl;

R_4, R_6 and R_7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl;

R_5 is selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, alkylsulfonyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and

A is a 5- or 6-membered partially unsaturated or aromatic heterocyclic ring or a 5- or 6- membered partially unsaturated carbocyclic ring,

wherein if A is a 6-membered partially unsaturated carbocyclic ring then at least one of R_4 to R_7 is other than hydrogen,

or a pharmaceutically acceptable salt, addition compound or prodrug thereof.

4. (Amended) A compound according to claim 1, wherein R_3 is lower alkyl.

5. (Amended) A compound according to claim 1, wherein R_3 is methyl.

6. (Amended) A compound according to claim 1, wherein R_4 is selected from hydrogen, halogen, alkyl and alkoxy.

7. (Amended) A compound according to claim 1, wherein R_4 is hydrogen.

8. (Amended) A compound according to claim 1, wherein R_6 is selected from hydrogen and halogen.

9. (Amended) A compound according to claim 1, wherein R_7 is selected from hydrogen, halogen and alkoxy.

10. (Amended) A compound according to claim 1, wherein A is a 5- membered ring.

11. (Amended) A compound according to claim 1, wherein A is partially unsaturated.

12. (Amended) A compound according to claim 1, wherein A contains a heteroatom selected from N, O and S.

A2 Cont'd

13. (Amended) A compound according to claim 1, wherein A is a 5- membered partially unsaturated carbocyclic ring, a 5- membered partially unsaturated or aromatic heterocyclic ring or a 6- membered partially unsaturated carbocyclic ring.

B2

14. (Amended) A compound according to claim 1, wherein A is selected from cyclopentenyl, cyclohexenyl, thiacyclohexenyl and thienyl.

15. (Amended) A compound according to claim 1 which is selected from the group consisting of (*S*)-1-(7,8-difluoro-1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*S*)-1-(7-fluoro-1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*S*)-1-(8-chloro-1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*S*)-1-(6-methoxy-1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*S*)-1-(7-fluoro-6-methoxy-1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*S*)-1-(7-fluoro-8-methoxy-1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*S*)-1-(8-chloro-7-fluoro-1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine, (*S*)-1-(1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine and (*R*)-1-(1,2,3,4-tetrahydrocyclopent[*b*]indol-4-yl)-2-propylamine.

---

18. (Amended) A method according to claim 25 wherein the disorders of the central nervous system are selected from the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioural disorders, behavioural disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

A3

19. (Amended) A method according to claim 25 wherein the damage to the central nervous system is by trauma, stroke, neurodegenerative diseases or toxic or infective CNS diseases.

A3 cont'd

20. (Amended) A method according to claim 19 wherein said toxic or infective CNS disease is encephalitis or meningitis.

21. (Amended) A method according to claim 25 wherein the cardiovascular disorder is thrombosis.

22. (Amended) A method according to claim 25 wherein the gastrointestinal disorder is dysfunction of gastrointestinal motility.

A4

25. (Amended) A method of treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, comprising administering to a patient in need of such treatment an effective dose of a compound of formula (I) as set out in claim 1.

A5

27. (Amended) A method according to claim 25 wherein said treatment is prophylactic treatment.

A6

29. (Amended) A pharmaceutical composition comprising a compound of formula (I) as set out in claim 1, in combination with a pharmaceutically acceptable carrier or excipient.

30. (Amended) A method of making a pharmaceutical composition, comprising combining a compound of formula (I) as set out in claim 1 with a pharmaceutically acceptable carrier or excipient.